US FDA sends 25 letters to telehealth companies over claims on compounded weight-loss drugs

Live updates

1. 1d ago

   FDA issues 25 warning letters to telehealth firms over compounded weight-loss drugs

   The US FDA sent 25 warning letters to telehealth companies making misleading claims about compounded versions of diabetes and weight loss drugs. These products target versions of medications from Novo Nordisk and Eli Lilly. A primary-source database now tracks these letters.

   What's confirmed:

   • The US FDA issued 25 warning letters to telehealth companies for marketing false and misleading claims about compounded versions of Eli Lilly and Novo Nordisk weight loss and diabetes drugs.
   • An independently maintained database links to the original fda.gov letters issued to compounded GLP-1 telehealth providers.
   confidence 100%
2. 2d ago

   FDA Issues 25 Warning Letters to Telehealth Firms Over GLP-1 Marketing

   The FDA is targeting telehealth companies that market compounded GLP-1 products like semaglutide and tirzepatide. Regulators are focused on false or misleading claims that suggest these compounded versions are equivalent to FDA-approved drugs. This effort is part of a broader initiative to curb misleading direct-to-consumer pharmaceutical ads.

   What's confirmed:

   • The FDA issued 25 warning letters to companies marketing compounded GLP-1 products.
   • Targeted medications include semaglutide and tirzepatide.
   • The agency is challenging marketing claims that lead consumers to believe compounded products are equivalent to FDA-approved drugs.
   • The FDA is working to rein in misleading direct-to-consumer pharmaceutical advertisements.
   confidence 100%
3. 3d ago

   FDA Issues 25 Warning Letters to Telehealth Firms Over Compounded GLP-1 Claims

   The US FDA sent 25 warning letters to telehealth companies for making false and misleading claims about compounded weight-loss and diabetes drugs. These copycat versions of medications from Eli Lilly and Novo Nordisk are not proven to be safe, effective, or of consistent quality. The agency is cracking down on the unauthorized marketing of these GLP-1 receptor agonist drugs.

   What's confirmed:

   • The FDA issued 25 warning letters to telehealth companies for marketing false and misleading claims about compounded versions of weight loss and diabetes drugs.
   • The warning letters targeted compounded versions of drugs from Eli Lilly and Novo Nordisk.
   • The FDA stated that these compounded products have not been proven to be safe, effective, or of consistent quality, unlike FDA-approved drugs.
   • The FDA cited more than two dozen telehealth companies for marketing compounded glucagon-like peptide-1 receptor agonist drugs without authorization.

   Still unconfirmed:

   • Life-threatening GLP-1 overdoses are increasing.
   • Some consumers have been scammed while buying GLP-1s online.
   confidence 100%